Patents by Inventor Lars Skattebol
Lars Skattebol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10472314Abstract: Using a combination of Kumada, Suzuki and Biellmann chemistry, various menaquinones can synthesized rapidly and with stereochemical integrity offering a new way of preparing these vitamin K2 components for the pharmaceutical market. In one embodiment a process for the preparation of a compound of formula (I) is defined including a step in which (i) a compound of formula (II) is reacted with a compound of formula (III) wherein R is an alkyl group; LG is a leaving group; m is an integer from 0 to 8; n is an integer of from 0 to 9; and X is hydrogen, halide, hydroxyl or protected hydroxyl; in the presence of a copper, nickel or palladium catalyst.Type: GrantFiled: June 20, 2017Date of Patent: November 12, 2019Assignee: KAPPA BIOSCIENCE ASInventors: Lars Skattebol, Inger Reidun Aukrust, Marcel Sandberg
-
Publication number: 20170283354Abstract: Using a combination of Kumada, Suzuki and Biellmann chemistry, various menaquinones can synthesised rapidly and with stereochemical integrity offering a new way of preparing these vitamin K2 components for the pharmaceutical market. In one embodiment a process for the preparation of a compound of formula (I) is defined including a step in which (i) a compound of formula (II) is reacted with a compound of formula (III) wherein R is an alkyl group; LG is a leaving group; m is an integer from 0 to 8; n is an integer of from 0 to 9; and X is hydrogen, halide, hydroxyl or protected hydroxyl; in the presence of a copper, nickel or palladium catalyst.Type: ApplicationFiled: June 20, 2017Publication date: October 5, 2017Inventors: Lars SKATTEBOL, Inger Reidun AUKRUST, Marcel SANDBERG
-
Patent number: 9375409Abstract: Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X (Wherein R is a C16-24 unsaturated hydrocarbon group optionally interrupted ?, ?, ?, or ? to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO2 said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group) in the manufacture of a medicament for the treatment of psoriasis.Type: GrantFiled: September 16, 2014Date of Patent: June 28, 2016Assignee: Avexxin ASInventors: Berit Johansen, Marit Anthonsen, Wenche Sjursen, Anne K. Holmeide, Lars Skattebol
-
Publication number: 20150210620Abstract: Using a combination of Kumada, Suzuki and Biellmann chemistry, various menaquinones can synthesised rapidly and with stereochemical integrity offering a new way of preparing these vitamin K2 components for the pharmaceutical market. In one embodiment a process for the preparation of a compound of formula (I) is defined including a step in which (i) a compound of formula (II) is reacted with a compound of formula (III) wherein R is an alkyl group; LG is a leaving group; m is an integer from 0 to 8; n is an integer of from 0 to 9; and X is hydrogen, halide, hydroxyl or protected hydroxyl; in the presence of a copper, nickel or palladium catalyst.Type: ApplicationFiled: April 8, 2015Publication date: July 30, 2015Inventors: Lars SKATTEBOL, Inger Reidun AUKRUST, Marcel SANDBERG
-
Publication number: 20150202165Abstract: Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X (Wherein R is a C16-24 unsaturated hydrocarbon group optionally interrupted ?, ?, ?, or ? to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO2 said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group) in the manufacture of a medicament for the treatment of psoriasis.Type: ApplicationFiled: September 16, 2014Publication date: July 23, 2015Inventors: Berit Johansen, Marit Anthonsen, Wenche Sjursen, Anne K. Holmeide, Lars Skattebol
-
Patent number: 9012693Abstract: Using a combination of Kumada, Suzuki and Biellmann chemistry, various menaquinones can synthesized rapidly and with stereochemical integrity offering a new way of preparing these vitamin K2 components for the pharmaceutical market. In one embodiment a process for the preparation of a compound of formula (I) is defined including a step in which (i) a compound of formula (II) is reacted formula (III) wherein R is an alkyl group; LG is a leaving group; m is an integer from 0 to 8; n is an integer from 0 to 9; and X is hydrogen, halide, hydroxyl or protected hydroxyl; in the presence of a copper, nickel or palladium catalyst.Type: GrantFiled: September 24, 2009Date of Patent: April 21, 2015Assignee: Kappa Bioscience ASInventors: Lars Skattebol, Inger Reidun Aukrust, Marcel Sandberg
-
Patent number: 8865768Abstract: Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X (Wherein R is a C16-24 unsaturated hydrocarbon group optionally interrupted by ?, ?, ?, or ? to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO2 said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group) in the manufacture of a medicament for the treatment of psoriasis.Type: GrantFiled: August 2, 2013Date of Patent: October 21, 2014Assignee: Avexxin ASInventors: Berit Johansen, Marit Anthonsen, Wenche Sjursen, Anne K. Holmeide, Lars Skattebol
-
Publication number: 20130324613Abstract: Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X (Wherein R is a C16-24 unsaturated hydrocarbon group optionally interrupted by ?, ?, ?, or ? to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO2 said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group) in the manufacture of a medicament for the treatment of psoriasis.Type: ApplicationFiled: August 2, 2013Publication date: December 5, 2013Applicant: Avexxin ASInventors: Berit Johansen, Marit Anthonsen, Wenche Sjursen, Anne Kristen Holmeide, Lars Skattebol
-
Patent number: 8524776Abstract: Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X) (Wherein R is a C16-24 unsaturated hydrocarbon group optionally interrupted by ?, ?, ?, or ? to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO2 said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group) in the manufacture of a medicament for the treatment of psoriasis.Type: GrantFiled: February 26, 2010Date of Patent: September 3, 2013Assignee: Avexxin ASInventors: Berit Johansen, Marit Anthonsen, Wenche Sjursen, Anne Kristen Holmeide, Lars Skattebol
-
Publication number: 20110207967Abstract: Using a combination of Kumada, Suzuki and Biellmann chemistry, various menaquinones can synthesised rapidly and with stereochemical integrity offering a new way of preparing these vitamin K2 components for the pharmaceutical market. In one embodiment a process for the preparation of a compound of formula (I) is defined including a step in which (i) a compound of formula (II) is reacted formula (III) wherein R is an alkyl group; LG is a leaving group; m is an integer from 0 to 8; n is an integer of from 0 to 9; and X is hydrogen, halide, hydroxyl or protected hydroxyl; in the presence of a copper, nickel or palladium catalyst.Type: ApplicationFiled: September 24, 2009Publication date: August 25, 2011Inventors: Lars Skattebol, Inger Aukrust, Marcel Sandberg
-
Publication number: 20100152293Abstract: Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X) (Wherein R is a C16-24 unsaturated hydrocarbon group optionally interrupted by ?, ?, ?, or ? to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO2 said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group) in the manufacture of a medicament for the treatment of psoriasis.Type: ApplicationFiled: February 26, 2010Publication date: June 17, 2010Applicant: Avexxin ASInventors: Berit Johansen, Marit Anthonsen, Wenche Sjursen, Anne Kristen Holmeide, Lars Skattebol
-
Patent number: 7687543Abstract: Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X (Wherein R is a C16-24 unsaturated hydrocarbon group optionally interrupted ?, ?, ?, or ? to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO2 said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group) in the manufacture of a medicament for the treatment of psoriasis.Type: GrantFiled: January 29, 2003Date of Patent: March 30, 2010Assignee: Avexxin ASInventors: Berit Johansen, Marit Anthonsen, Wenche Sjursen, Anne Kristen Holmeide, Lars Skattebol
-
Publication number: 20050165116Abstract: Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X (Wherein R is a C16-24 unsaturated hydrocarbon group optionally interrupted ?, ?, ?, or ? to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO2 said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group) in the manufacture of a medicament for the treatment of psoriasis.Type: ApplicationFiled: January 29, 2003Publication date: July 28, 2005Inventors: Berit Johansen, Marit Anthonsen, Wenche Sjursen, Anne Holmeide, Lars Skattebol
-
Patent number: 6548042Abstract: The present invention provides a pharmaceutical compound, or pharmaceutically acceptable salt thereof, for use in medicine, wherein said compound is of formula I wherein R is a pharmaceutically active moiety; Ar is an aromatic moiety; X is a linker group; and Y is a moiety comprising two phosphonate groups. Further aspects of the invention relate to a method for palliative and curative treatment of bone disorders and cancer related disorders, such as breast cancer.Type: GrantFiled: July 9, 2001Date of Patent: April 15, 2003Inventors: Erik {haeck over (A)}rstad, Lars Skattebøl
-
Publication number: 20020042539Abstract: The present invention provides a pharmaceutical compound, or pharmaceutically acceptable salt thereof, for use in medicine, wherein said compound is of formula I 1Type: ApplicationFiled: July 9, 2001Publication date: April 11, 2002Inventors: Erik Arstad, Lars Skattebol
-
Patent number: 4578484Abstract: New process for preparing the pheromone active compound lineatin (3,3,7-trimethyl-2,9-dioxatricyclo[3,3,1,0.sup.4,7 ]-nonane), by reacting a 2,2-dimethyl-3,4-pentadienal of formula 1, in which R.sub.1 and R.sub.2 is each hydrogen or lower alkyl, with .beta.-methylallyl magnesium halide; the formed 2,5,5-trimethylocta-1,6,7-trien-4-ol derivative of formula 2 is subjected to oxidation which does not attack the double bonds; the formed 2,5,5-trimethylocta-1,6,7-trien-4-one derivative of formula 3 is subjected to pyrolysis; the formed 1,4,4-trimethyl-6-methylenebicyclo[3,2,0]heptan-3-one derivative of formula 4 is subjected to oxidation; the resulting 5,5,9-trimethyl-2,6-dioxa-7-oxo-bicyclo[4,2,0]octylspiro[2,7]-decane derivative of formula 5 is subjected to oxidation; the resulting 1,5,5-trimethyl-4-oxabicyclo[4,2,0]-octan-3,7-dione of formula 6 is reduced in a per se known manner to lineatin of formula 7. Compounds 2, 3, 4 and 5 are novel.Type: GrantFiled: November 15, 1984Date of Patent: March 25, 1986Assignee: Borregaard Industries LimitedInventors: Lars Skattebol, Yngve Stenstrom